Omega Fund, including Director Stampacchia, invests $2.5M in ImageneBio PIPE

summarizeSummary

Omega Fund, a major institutional investor and a director, invested $2.5 million in ImageneBio's recent $30 million private placement, increasing their stake to 8.4%.

check_boxKey Events · Ownership and Investor Activity · IMA

• Significant Investment in PIPE

  Omega Fund, a major institutional investor, acquired pre-funded warrants worth approximately $2.5 million in ImageneBio's recent $30 million private placement.

• Increased Ownership Stake

  This investment, combined with existing holdings, brings Omega Fund's beneficial ownership to 8.4% of ImageneBio's common stock.

• Director Involvement

  Otello Stampacchia, a director of ImageneBio, is part of the reporting group, signaling insider confidence in the financing.

• Context of Capital Raise

  This filing provides specific details of a key investor's participation in the $30 million private placement announced on April 13, 2026, which is crucial for the company's financial runway.

auto_awesomeAnalysis · IMA · Life Sciences

This Schedule 13D filing reveals that Omega Fund, a significant institutional investor with a board representative (Otello Stampacchia), acquired approximately $2.5 million in pre-funded warrants as part of ImageneBio's recently announced $30 million private placement. This substantial investment, representing 3.77% of the company's market capitalization, increases Omega Fund's beneficial ownership to 8.4%. The participation of a major institutional investor and a director in this capital raise provides a strong signal of confidence in the company's future, particularly as it secures crucial funding for its operations and clinical development, following the positive Phase 1b/2a clinical results for IMG-007.